Could some one please answer the following questions; -The contact information for the vaccine recruiter? -What is the salary range? -Bonus Plan? Thank You
We are filling those spots internally. If we fire too many people, or enough people are sick & tired of the BS and layoffs, well, maybe external candidates will get another look.
Apply on Pfizer career site. They are definitely hiring external candidates. Many in PC didn't make the cut.
saw a couple of posts in my area. Whats the base range and target commission? Is this prevnar for adults or children?
As you can read below they got new recommendations so docs HAVE to give it. That's the nature of the vaccine business. Once you have that the selling aspect diminishes ( and service / order taker role kicks in) since most docs follow the guidelines. Not quite rock solid as pediatric recommendations where the doctors fear of lawsuits and invasive disease, as well as school/daycare requirements for entry drives the usage once it's recommended. Never the less, it will still get used much more now than it did prior to the recommendations (hence the expansion). If another company comes out with a conjugate vaccine then it will get interesting. Most docs hate Pfizer/Wyeth for the way they raised the price of this vaccine and will jump to a competitor if given the chance. August 27, 2014 02:08 pm Chris Crawford – The CDC's Advisory Committee on Immunization Practices (ACIP) held a special meeting(www.cdc.gov) Aug. 13 to discuss and vote on the use of pneumococcal vaccines in older adults. The meeting concluded with the committee recommending routine immunization with 13-valent pneumococcal conjugate vaccine (PCV13) for adults 65 or older. First, the recommendation calls for offering a dose of the PCV13 vaccination, marketed by Pfizer Inc. as Prevnar 13, to adults age 65 or older who have not previously received a pneumococcal vaccine or whose previous vaccination history is unknown. The recommendation then notes that physicians should recommend a dose of the 23-valent pneumococcal polysaccharide vaccine (PPSV23), marketed by Merck and Co. as Pneumovax, for these patients six to 12 months after PCV13 vaccination. Secondly, the recommendation states that if a patient 65 or older has not previously received the PCV13 vaccine but has received one or more doses of PPSV23, that patient should receive a dose of PCV13 at least one year after administration of the most recent dose of PPSV23. If an additional dose of PPSV23 is indicated, that dose should be given six to 12 months after PCV13 vaccination and at least five years after the most recent dose of PPSV23.
